 LAS VEGAS, Sept. 28, 2021 PRNewswire -- JanOne Inc. Nasdaq: JAN, a company that focuses on the development of treatments for conditions that cause severe pain in conjunction with its continuing focus on the development of drugs with non-addictive, pain-relieving properties today announced that it is revising its development strategy based on recent communications with the U.S. Food and Drug administration FDA for its upcoming clinical trial of lead drug candidate JAN101 as a treatment for Peripheral Artery Disease PAD. 